PF-5274857 773 Ribociclib treatment of two neuroblastoma

Ribociclib treatment of two neuroblastoma cell lines (BE2C and IMR5) with demonstrated sensitivity to CDK4/6 inhibition results in a dose-dependent accumulation of cells in the G0/G1 phase of the cell cycle

The levels of inflammatory cytokines IL-1

14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one

and DNA-PK

and favorable mouse PK profile

PF-5274857 773 Ribociclib treatment of two neuroblastomaPF 5274857 is a potent, orally active and selective hedgehog (Hh) signaling pathway inhibitor with an IC50 of 5. 8 nM and a Ki of 4. 6 nM. PF 5274857 was found to effectively penetrate the blood brain barrier and inhibit Smo activity in the brain of primary medulloblastoma mice, resulting in improved animal survival rates. PF 5274857 was orally available and metabolically stable in vivo. PF 5274857 is a potentially attractive clinical candidate for